Employees: 1,982
Size KYORIN Pharmaceutical (4569.T) is a Japan Health Care company (Pharmaceuticals: Major) with a market value of $360M, the 1242nd largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥1,108 on 18 Nov 2026.
Performance Over six months the shares fell 22.0%, against -23.8% for the median peer and -1.4% for the Japan market (cap-weighted) — 8th highest of 19 in its peer set.
Growth Revenue fell 6.5% over the last twelve months (peer median -1.1%); the operating margin is 2.0% (peer median -13.0%).
Valuation It trades at 35.5× forward earnings against a peer median of 16.0× (2nd most expensive of 5).
Price implies For today's price to make sense, revenue must grow about 7% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is +2 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 3.7 points below its cost of capital (5.0% WACC).
Next results Next results expected around 4 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥125B | ¥126B | ¥130B | ¥120B | ¥113B |
| Revenue growth | — | -3% | +9% | +6% | — |
| Gross profit | ¥49.1B | ¥51.6B | ¥59.5B | ¥51.6B | ¥50.2B |
| EBITDA | ¥7.19B | ¥8.22B | ¥17.1B | ¥10.5B | ¥8.96B |
| Net income | ¥388M | ¥3.45B | ¥9.09B | ¥5.47B | ¥4.72B |
| Free cash flow | n/a | ¥2.52B | -¥2.19B | -¥4.23B | -¥4.32B |
| Capital expenditure | n/a | ¥3.98B | ¥6.29B | ¥6.25B | ¥9.40B |
| Total debt | ¥23.2B | ¥23.8B | ¥28.4B | ¥20.9B | ¥21.3B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 4569.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +0.2% | -13.3% | 3rd highest of 20 |
| 6-month return | -22.0% | -23.8% | 8th highest of 19 |
| Distance from 52-week high | -35.8% | -41.3% | 9th highest of 21 |
| Revenue growth (TTM) | -6.5% | -1.1% | 9th lowest of 18 |
| Operating margin | 2.0% | -13.0% | 7th highest of 18 |
| Forward P/E | 35.5× | 16.0× | 2nd most expensive of 5 |
| Growth the price implies (Req g, 7 yrs) | 6.7% | 5.8% | 4th least demanding of 7 |
| Growth delivered (Del g) | +4.2% | +1.7% | 3rd highest of 7 |
| Hurdle (Req g minus delivered) | +2.5 pp | +0.2 pp | 3rd most demanding of 7 |
| ROIC minus cost of capital | -3.7 pp | -7.2 pp | 7th highest of 16 |
| EV / EBITDA | 8.0× | 15.7× | 2nd cheapest of 6 |
| Net debt / EBITDA | -0.0× | 0.2× | 3rd least indebted of 6 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| KYORIN Pharmaceutical 4569.T | Japan | $360M | -22% | -6% | 2% | 35.5× | 6.7% | +4.2% |
| Unichem Laboratories UNICHEMLAB.NS | India | $361M | +28% | +6% | 5% | n/a | n/a | n/a |
| Tuoxin Pharmaceutical 301089.SZ | China | $363M | -28% | +17% | -20% | n/a | n/a | n/a |
| Anhui Fengyuan Pharmaceutical 000153.SZ | China | $355M | -17% | -24% | 3% | n/a | 3.6% | +3.1% |
| Pharmicell 005690.KS | South Korea | $364M | -55% | +46% | 32% | 8.2× | -7.9% | +24.8% |
| ASKA Pharmaceutical 4886.T | Japan | $354M | -24% | +11% | n/a | 12.9× | n/a | n/a |
| Guangdong Lifestrong Pharmacy 301111.SZ | China | $368M | -33% | +7% | -2% | n/a | n/a | n/a |
| 6467 6467.TW | Taiwan | $368M | n/a | n/a | -2,618% | n/a | n/a | n/a |
| Guizhou Yibai Pharmaceutical 600594.SS | China | $351M | -23% | -26% | -15% | n/a | 8.0% | -11.3% |
| MapLight Therapeutics MPLT | United States | $370M | -76% | n/a | n/a | n/a | n/a | n/a |
| Tiansheng Pharmaceutical 002872.SZ | China | $371M | -1% | -1% | -13% | n/a | 22.2% | -15.7% |
| ARS Pharmaceuticals SPRY | United States | $371M | -53% | -14% | -162% | n/a | n/a | n/a |
| Puma Biotechnology PBYI | United States | $373M | +3% | +9% | 11% | 19.0× | 0.1% | +0.3% |
| Jiangsu Bioperfectus Technologies 688399.SS | China | $374M | -51% | -8% | -23% | n/a | n/a | n/a |
| Opus Genetics IRD | United States | $379M | -22% | -46% | -778% | n/a | n/a | n/a |
| JCR Pharmaceuticals 4552.T | Japan | $379M | -5% | +3% | -14% | 398.3× | n/a | n/a |
| Lifecome Biochemistry 002868.SZ | China | $384M | -54% | -23% | -3% | n/a | n/a | n/a |
| SanBio 4592.T | Japan | $386M | -55% | n/a | n/a | n/a | n/a | n/a |
| Gansu Longshenrongfa Pharmaceutical Industry 300534.SZ | China | $386M | -2% | -21% | 8% | n/a | 20.9% | +28.2% |
| Shukra Pharmaceuticals SHUKRAPHAR.NS | India | $387M | n/a | +222% | 54% | n/a | n/a | n/a |
| iX Biopharma 42C.SI | Singapore | $387M | +28% | -12% | -140% | n/a | n/a | n/a |